Abstract 385P
Background
Introduction: Breast Cancer is one of the most common cancer in Iranian women. Whole genome association study of breast cancer have recognized various single nucleotide polymorphisms (SNPs) that are related with increased breast cancer risk in the population. This study aimed at assessing the correlation between caspase-8 (CASP8) gene polymorphisms (rs3754934 and rs12990906) and the pathogenesis of breast cancer in Northeast of Iran.
Methods
In a case- control study a total of 450 breast cancer cases and 553 healthy subjects were included in this study. Polymorphisms were genotyped by amplification-refractory mutation system (ARMS). The chi-squared test was used to calculate Odds ratio (OR) with 95% confidence interval to determine the relationship between CASP8 polymorphisms and breast cancer risk.
Results
According to the results, after adjustment for confounding factors, rs3754934 in dominant model (CA+AA vs. CC) [p = 0.004, OR = 0.49 95% CI (0.27-0.78)] and rs12990906 in allelic model (T vs. C) [p = 0.026, OR = 1.27, 95%CI (1.03-1.58)] were associated with the risk of breast cancer in this population. We did not find any association with breast cancer risk factors, clinical and pathologic features and prognosis and considered polymorphisms.
Conclusions
Polymorphisms of CASP8 gene may have a crucial role in association with the risk of breast cancer. However, further larger studies can confirm such findings. An understanding of the mode of action of these variants will aid individual-level breast cancer risk prediction.
Clinical trial identification
Editorial acknowledgement
The authors thank all participants in this research. We would also like to thank Mashhad University of Medical Sciences and Omid hospital to support the project.
Legal entity responsible for the study
Mashhad University of Medical Sciences.
Funding
Mashhad University of Medical Sciences.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract